A Prospective Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Heart Transplant Patients

What this Trial Is About

This research aims to understand how abnormal lipid metabolism, which is common after organ transplantation, relates to transplant rejection and failure. It focuses on cardiac transplant patients who often experience lipid changes due to immunotherapy. The study explores the interaction between PCSK9, lipid disorders, and immune responses, which may contribute to transplant rejection. The goal is to clarify these links to improve management of lipids during and after surgery. The study involves tracking heart transplant patients over a long term to observe lipid changes and their connection to rejection. It expands testing beyond traditional lipid assays to include transcriptomic, proteomic, and metabolomic analyses to better understand PCSK9's role in dyslipidemia. Single-cell sequencing is used to investigate how these lipid changes affect T-cell-mediated rejection of the transplanted heart. Participants will be followed for four years, during which blood lipid levels and graft/patient survival will be monitored. Additional assessments include measuring heart function through left ventricular ejection fraction at rest. This observational study collects detailed biological data and monitors health outcomes to deepen understanding of how lipid metabolism influences transplant success and patient survival.

A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients